CUX1-ALK:非小细胞肺癌中对克唑替尼应答的新型ALK重排
本研究通过靶向416个泛癌基因及16个常见重排基因内含子的二代测序,在一例肺腺癌患者中鉴定出新型CUX1-ALK融合基因,并经RNA测序和RT-PCR确认。293T细胞实验证实该融合蛋白可自磷酸化并激活ALK下游MAPK、JAK-STAT和PI3K/AKT通路,且可被克唑替尼抑制。该患者对克唑替尼显示优异应答,无进展生存期达20个月。
要点
- 在肺腺癌患者中鉴定出新型CUX1-ALK融合基因。
- CUX1-ALK融合蛋白可激活ALK下游信号通路并被克唑替尼抑制。
- 该患者对克唑替尼应答,无进展生存期20个月。
核心结论
- 在非小细胞肺癌患者中发现新型CUX1-ALK融合基因,该融合基因具有致癌能力且对克唑替尼敏感。
研究设计与样本
- 采用靶向416个泛癌基因及16个常见重排基因内含子的二代测序,在一例肺腺癌患者中鉴定CUX1-ALK融合基因。
- 通过RNA测序确定融合转录本,RT-PCR确认,并在293T细胞中验证融合基因的致癌能力。
主要发现
- RNA测序显示CUX1内含子8的97个核苷酸片段插入ALK外显子20第53位核苷酸之前。
- 293T细胞中CUX1-ALK融合蛋白自磷酸化并激活MAPK、JAK-STAT和PI3K/AKT下游信号通路。
- 上述信号通路激活可被克唑替尼抑制。
- 该患者对克唑替尼显示优异应答,无进展生存期为20个月。
临床怎么用
- 对NSCLC患者进行包含ALK重排的全面基因组检测有助于发现罕见ALK融合变异。
- 携带CUX1-ALK融合的NSCLC患者可能从克唑替尼治疗中获益。
局限性
- 本研究仅基于一例患者,CUX1-ALK融合的频率和临床意义需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung cancer is the leading cause of cancer-related deaths worldwide. ALK receptor tyrosine kinase gene (ALK) rearrangement has been identified in 3% to 5% of patients with NSCLC. The most common ALK rearrangement is echinoderm microtubule associated protein like 4 (EML4)-ALK, with several variants that can be targeted by the tyrosine kinase inhibitor crizotinib. METHODS: In this study using comprehensive next-generation sequencing targeting 416 pan-cancer genes and introns of 16 genes frequently rearranged in cancer, we identified a novel cut-like homeobox 1 gene (CUX1)-ALK fusion gene in a patient with lung adenocarcinoma. The exact CUX1-ALK fusion transcript was determined by RNA sequencing and confirmed by reverse-transcriptase polymerase chain reaction. The oncogenic ability of CUX1-ALK fusion gene was further validated in cells of the line 293T for the activation of anaplastic lymphoma kinase (ALK) self-phosphorylation and downstream signaling pathways. RESULTS: After detection of the CUX1-ALK fusion gene, RNA sequencing analysis of formalin-fixed paraffin-embedded sections from the primary tumor specimen was applied to reveal a 97-nucleotide fragment from CUX1 intron 8 inserted before the nucleotide 53 position in ALK exon 20. Expression of the cut-like homeobox 1-ALK fusion protein in 293T cells confirmed the self-phosphorylation of the fusion protein and the activation of ALK downstream signaling pathways, including the mitogen-activated protein kinase, Janus kinase-signal transducer and activator of transcription, and phosphoinositide 3-kinase/AKT signaling pathways, which could all be inhibited by the addition of crizotinib. Furthermore, the patient showed a superior response to crizotinib, with a progression-free survival of 20 months. CONCLUSIONS: This study provides the novel finding of a CUX1-ALK fusion gene from a patient with NSCLC that could provide personalized treatment solutions for the maximum benefit to patients with NSCLC.
引用
- Zhang M, Wang Q, Ding Y, et al. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30010043. doi:10.1016/j.jtho.2018.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。